Skip to main content
. Author manuscript; available in PMC: 2016 Jul 15.
Published in final edited form as: Cancer Res. 2015 May 12;75(14):2897–2906. doi: 10.1158/0008-5472.CAN-14-2860

Figure 7.

Figure 7

The combination of decitabine and navitoclax shows activity in a xenograft mouse model derived from a KRAS-mutant ovarian cancer cell line. A, tumor volume as measured by caliper of low dose decitabine (0.2 mg/kg, SC, 3x per week) or vehicle administered for four weeks in a subcutaneous xenograft model using a KRAS-mutant cell line (OVCAR8) (*, p = 0.02; Mann-Whitney). Tumors were excised after four weeks of treatment. B, tumor volume as measured by caliper of low-dose decitabine (0.2 mg/kg in 7A and 7B SC, 3x per week), navitoclax (100 mg/kg IP, 5x per week) or vehicle administered alone or in combination for four weeks in a subcutaneous xenograft model using a KRAS-mutant cell line (OVCAR8) (*, p < 0.03; t-test, **, p < 0.001; t-test). Week four treatment omitted one injection of decitabine and two injections of navitoclax. Tumors were excised after four weeks of treatment.